News2023-01-30T15:43:55+01:00

NEWS

You can follow the latest news of MicroViable in this section

Microviable received the MRR High-Impact Paper Award

13 de March de 2026|

Microviable has received the 2025 Microbiome Research Reports High-Impact Paper Award, a recognition to an outstanding scientific review manuscript published in 2025 in the journal Microbiome Research Reports. Our CTO, David Ríos Covián, PhD, lead [...]

Microviable present at the Microbiome Times Partnering Forum

10 de March de 2026|

During March 18-19th, Microviable will be attending the Microbiome Times Partnering Forum taking place in Copenhagen, joining other cutting-edge biotech companies, VCs, and pharma companies during the two days of the event. Microviable will have [...]

Two Projects funded under CanSERV European call

12 de February de 2026|

Microviable obtained two projects funded under CanSERV European call focused on "Reaching and Understanding of Cancer".  We are proud to announce that our research proposal “Exploring the relationships between anti-PD1 responders and gut microbiota: intervention [...]

Projects awarded SEKUENS

11 de February de 2026|

At Microviable we are proud and thankful to SEKUENS, Agencia de Ciencia, Competitividad Empresarial e Innovación del Principado de Asturias, for the four projects approved in 2025 with competitive funding! We will keep pushing for [...]

Claudio Hidalgo presenting at LSX Inv€$stival Showcase

14 de November de 2025|

Microviable Therapeutics will be attending LSX Inv€$tival Showcase Claudio Hidalgo, PhD, cofounder and CEO and Noelia Martínez, PhD, cofounder and R&D Director at Microviable Therapeutics, will be attending LSX Inv€$tival Showcase in London on November [...]

MICROVIABLE THERAPEUTICS

CONTACT US

Go to Top